BioSpace News Archive

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced that the company is scheduled to present at the virtual Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020 at 9:50 a.m. ET.

There are a number of reasons why the global home healthcare market is predicted to multiply in the years to come.

Medical traction is a therapeutic method used in treating several situations such as muscle contracture, bone fractures, bone deformities and long-duration muscle spasms.

Although not every medical isotopes are particularly radioactive in nature, nuclear medicines or radiopharmaceuticals make for one of the common drugs that are used for the diagnosis of dysfunctions in human body tissue.

According to the report, the global drug discovery outsourcing market was valued at US$ 4.5 Bn in 2019. It is projected to expand at a high CAGR during the forecast period.

According to the report, the global neuropathic pain therapeutics market was valued at US$ 5.8 Bn in 2019 and is projected to expand at a CAGR of ~5% from 2020 to 2030.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp , Chairman and Chief Executive Officer, will present at the LD Micro 500 Virtual Investor Conference being held virtu

Lantern Pharma (NASDAQ: LTRN) , a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (“A.I.”) platform to transform the pace, risk and cost of oncology drug discovery and development, and identify patients who will benefit from its targeted oncology drug candidates, announced today that Panna Sh

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced additional data indicating that obeticholic acid (OCA) helped patients with nonalcoholic steatohepatitis (NASH) achieve sustained improvements in liver biochemistry and noninvasive markers of liver fibrosis over two years of treatment.

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will present a corporate overview at the LD Micro 500 Virtual Conference, being held virtually September 1 – 4, 2020.